BridgeBio’s Attruby Could Benefit From ‘Best-Case’ Label, Lower Price

The US FDA approved the TTR-stabilizing drug for ATTR-CM, with the drugmaker pricing it below that of Pfizer’s Vyndaqel/Vyndamax.

Gold "FDA approved" label — (Shutterstock)

BridgeBio’s Attruby (acoramidis) has the potential to be a highly competitive treatment for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) with its recent US Food and Drug Administration approval, thanks to the drug’s favorable labeling and lower price.

The FDA approved Attruby late on 22 November based on results from the Phase III ATTRibute-CM study, in which the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

02 Jul 2025

• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Pipeline Watch: Eleven Approvals And ADA Readouts Dominate

30 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Empty Promises: Five Drugs That Fell Short Of Their Sales Forecasts

30 Jun 2025

• By Edwin Elmhirst

Many assets underperform their pre-launch sales predictions, which can be disastrous to their developers and marketers. In this article, Scrip highlights several historic examples and the factors that influenced their poorer-than-expected performance.